Pall invests in virus inactivation technology:
This article was originally published in Clinica
Executive Summary
Pall Corporation has released $3 million in a milestone payment to VI Technologies as it enters Phase I clinical trials on its proprietary INACTINE red blood cell inactivation technology. VI Technologies, of Melville, New York, estimates that the potential market for virally-inactivated red blood cells could exceed $2 billion annually.